Thalassemia access in Pakistan, the Punjab registry, and where Reserve Meds fits
By Reserve Meds · Clinical and regulatory team · Last reviewed 2026-05-17
The thalassemia burden in Pakistan
Pakistan has one of the highest carrier rates for beta-thalassemia globally, with estimates of 5-7 percent population carrier prevalence and approximately 5,000-9,000 new transfusion-dependent thalassemia (TDT) births per year. Consanguineous marriage rates above 60 percent in many regions amplify the risk.
The Punjab Thalassaemia and other Genetic Disorders Prevention and Research Institute (PTPI), launched in 2017 and operating from Lahore, anchors the country's largest registry, carrier screening programme, and transfusion-centre coordination. Sindh Thalassemia Society, Fatimid Foundation, Kashif Iqbal Thalassaemia Care Centre (Karachi), and Husaini Blood Bank are major partners.
Standard-of-care: transfusion plus chelation
TDT patients typically receive packed red cell transfusions every 2-4 weeks from age 6-12 months for life, paired with iron chelation. Locally available chelators include deferasirox (Exjade and Asunra generics, FDA-equivalent regulated), deferiprone, and deferoxamine. The PTPI network coordinates transfusion access and provides subsidised or free chelation for registered patients.
Splenectomy, growth and endocrine surveillance, hepatitis B/C screening (high background prevalence), and cardiac MRI iron load assessment (T2*) are standard at tertiary centres including AKU, Shaukat Khanum, and Children's Hospital Lahore.
Where named-patient innovator imports come in
Luspatercept (Reblozyl) is FDA-approved for beta-thalassemia transfusion-dependent anemia in adults. It is not broadly registered for routine pharmacy dispensing in Pakistan and is typically accessed via DRAP Personal Use Import / Named Patient through the OIES portal. Reblozyl reduces transfusion burden in approximately one-third of eligible patients.
Casgevy (exagamglogene autotemcel) is the first FDA-approved CRISPR/Cas9 gene therapy for TDT and sickle cell disease. Treatment is currently delivered only at authorised treatment centres outside Pakistan; AKU and Shaukat Khanum have explored coordination pathways for international referral. Reserve Meds can support patient-family coordination but is not the treatment provider.
How Reserve Meds fits
Reserve Meds sources Reblozyl from US-licensed specialty wholesale partners under DSCSA chain-of-custody, files the DRAP OIES Special Permission application with the patient's haematologist, handles cold-chain shipping to PTPI / AKU / Shaukat Khanum / Indus pharmacy, and supports refill cadence over the multi-year treatment horizon.
We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. Clinical decisions remain with your haematologist and the PTPI multidisciplinary team. We are in pre-launch; cohort availability is limited.
Indicative timing and cost (cash-pay)
Indicative annual cash-pay cost for innovator Reblozyl: USD 175,000-210,000 drug-only at US WAC, with Reserve Meds concierge, DRAP filing, cold-chain shipping, and tertiary-centre delivery layered on top. In PKR at approximately 280 PKR/USD, that is roughly 4.9-5.9 crore rupees annually.
Indicative DRAP OIES Special Permission turnaround: 15-30 working days, with expedited 7-10 days for clinically urgent cases (severe transfusion burden, iron-overload complications, post-splenectomy decompensation).
State Bank of Pakistan Form FE-25 outward remittance for medical treatment is the typical FX instrument; Reserve Meds documentation supports the bank submission.
Documentation your haematologist needs
Beta-thalassemia diagnosis (HPLC HbF/HbA2, beta-globin gene mutation analysis where available), transfusion log with frequency and pre-transfusion Hb, ferritin trend, T2* cardiac MRI, hepatic iron concentration where available, prior chelator response, PMC registration, OIES Special Permission application. Reserve Meds supplies the documentation template.
Frequently asked
Is Casgevy available in Pakistan? Not as a domestic delivery option in 2026. Authorised treatment centres are currently outside Pakistan. International referral is possible but is a major undertaking; AKU and Shaukat Khanum can advise on coordination.
Does the Punjab Thalassaemia Prevention Programme cover Reblozyl? No, PTPI focuses on transfusion access, chelation subsidy, registry, and carrier screening. Innovator therapies like Reblozyl are accessed via named-patient pathways.
What about bone marrow / haematopoietic stem cell transplant in Pakistan? Allogeneic HSCT for thalassemia is offered at Armed Forces Bone Marrow Transplant Centre (Rawalpindi), Shaukat Khanum, and AKU for matched-sibling cases. Outcomes in well-selected patients are excellent. Casgevy is the alternative for patients without a matched donor.
How does carrier screening work in Pakistan? PTPI offers pre-marital and antenatal carrier screening across Punjab. Sindh and KP have parallel partner programmes. Both partners being carriers is the highest-risk scenario.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US to overseas). Composite case examples. Not medical advice.
Clinical and regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-05-17.